Likewise, no increased cancer risk due to sulfonylureas was apparent in a recent cohort study [59], but in light of the discussed contributory effect of hyperinsulinemia to the CRM–cancer connection, neither sulfonylureas nor insulin represent a prioritized treatment option for glucose control in patients at risk of cancer. Here, INS is linked to hyperinsulinism.